Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF 86 Operating Cash Flow per Share is $0.80 as of Jun. 2026. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $44.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 652 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 85.89% on this metric.
Xvivo Perfusion AB's operating cash flow per share for the
three
months ended in Jun. 2026 was $0.21.
Xvivo Perfusion AB's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.80.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Xvivo Perfusion AB was 202.00% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 50.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Xvivo Perfusion AB's Operating Cash Flow per Share or its related term are showing as below:
XVIPF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -7.1 Med: 26 Max: 50.3
Current: 50.3
During the past 13 years, Xvivo Perfusion AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was 50.30% per year. The lowest was -7.10% per year. And the median was 26.00% per year.
XVIPF's 3-Year OCF Growth Rate is ranked better than 85.89% of 652
companies
in the Medical Devices & Instruments industry
Industry Median: 12.4
vs XVIPF: 50.30
Xvivo Perfusion AB Operating Cash Flow per Share Related Terms
Xvivo Perfusion AB Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Operating Cash Flow per Share Chart
XVIPF vs ABT, SYK, MDT: Operating Cash Flow per Share Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.80 mean?
Xvivo Perfusion AB (XVIPF) has a Operating Cash Flow per Share of $0.80 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #92 out of 652 companies in the Medical Devices & Instruments industry, placing it in the top 14.1%.
Is Xvivo Perfusion AB's Operating Cash Flow per Share too high?
Xvivo Perfusion AB's current Operating Cash Flow per Share is $0.80. The Medical Devices & Instruments industry median Operating Cash Flow per Share is 12.40. Xvivo Perfusion AB's value of $0.80 is 93.5% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #92 out of 652 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Operating Cash Flow per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #92 out of 652 companies for Operating Cash Flow per Share. This places Xvivo Perfusion AB in the top 14% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 12.40. Xvivo Perfusion AB's value of $0.80 is 93.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Devices & Instruments company?
The median Operating Cash Flow per Share among Medical Devices & Instruments companies is 12.40, based on 652 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Operating Cash Flow per Share of $0.80 is 93.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Operating Cash Flow per Share is 12.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Operating Cash Flow per Share is $0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $44.36, compared to a current price of $24.50 — trading 44.8% below its estimated fair value. The current Operating Cash Flow per Share is $0.80 and 93.5% below the Medical Devices & Instruments industry median of 12.40. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Operating Cash Flow per Share is $0.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $24.50 is trading 44.8% below its estimated GF Value™ of $44.36.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Operating Cash Flow per Share: $0.80
GF Value™: $44.36 vs. price of $24.50 (44.8% below fair value)
Industry Position: 93.5% below the Medical Devices & Instruments median (#92 of 652)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
